To date, monotherapy with clinically available TKIs is unable to durably overcome resistance caused by secondary KIT/PDGFRA mutations in patients with advanced GIST for longer than 6 months on average, explaining our inability to obtain long-term disease control in the second-line or later lines of therapy. Here, PDGFRA is linked to gastrointestinal stromal tumor.